Spots Global Cancer Trial Database for zilovertamab vedotin
Every month we try and update this database with for zilovertamab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | NCT05406401 | Lymphoma, Large... | Zilovertamab Ve... Cyclophosphamid... Doxorubicin Rituximab Rituximab Biosi... Prednisone Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | NCT05458297 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Richter Transfo... | Zilovertamab ve... Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | NCT06395103 | B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma | Zilovertamab ve... | 6 Months - 25 Years | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | NCT05406401 | Lymphoma, Large... | Zilovertamab Ve... Cyclophosphamid... Doxorubicin Rituximab Rituximab Biosi... Prednisone Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | NCT06395103 | B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma | Zilovertamab ve... | 6 Months - 25 Years | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | NCT05562830 | Urothelial Carc... | Zilovertamab ve... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | NCT05458297 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Richter Transfo... | Zilovertamab ve... Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | NCT05406401 | Lymphoma, Large... | Zilovertamab Ve... Cyclophosphamid... Doxorubicin Rituximab Rituximab Biosi... Prednisone Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | NCT05139017 | DLBCL Diffuse Large B... | Zilovertamab ve... Rituximab Gemcitabine Oxaliplatin Bendamustine | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
